Aptahem has brought together a strong team of experts to take the development of Apta-1 to clinical Phase I/II. However, assuming that sufficient data is gathered on effect, toxicity and mechanism of action to attract interest, the initial goal is to identify a licencee partner or investor at the pre-clinical stage that is able to continue development through the latter, more costly clinical studies in Phase II/III and on to market launch. Aptahem’s business structure is flexible and cost efficient, with project management and scientific expertise within the company and co-operation with individual specialists and consultants brought in when needed. The contract research organisations and academic research groups with which Aptahem works are based worldwide, and are selected by competence, experience and cost structure.
Apta-1 is currently in the pre-clinical phase, and non-confidential discussions are being conducted with potential licencees and/or buyers.